NCT06790355Completed
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Feasibility of Blood-based Test for Multi-cancer Early Detection in Asymptomatic Screening Population（ProSight）: a Multi-centre Interventional Study
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2527 (actual)
- First submitted
- 12 Jan 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
- Diseases
- Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT06790355
What you commit to
- Study type: Interventional
- Participants enrolled: 2527
- From 1 Mar 2025 to the primary completion date, 31 Aug 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen
- Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrinotherapy for cancer is not an exclusion criterion.
- Recipients of anti-tumor therapy within 30 days prior to screen
- Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
- Recipients of blood transfusion within 7 days prior to screen
- Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw
Other illness
- Have definite contraindications of cancer screening examination and diagnostic procedures
- Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date
- With autoimmune diseases
- Unsuitable for this trial determined by the researchers (eg. hemorrhagic diseases)
Other
- Unable to comply with the protocol procedures
- Pregnancy or lactating women
Who the study is looking for
- 40-74 years old
- Able to provide a written informed consent and willing to comply with all parts of the protocol procedures
Age in the registry: 40 years to 74 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| Jiangsu Cancer Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.